This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Liquidia’s 8K filing here.
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read More
- Five stocks we like better than Liquidia
- Retail Stocks Investing, Explained
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How Investors Can Find the Best Cheap Dividend Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Buy Cheap Stocks Step by Step
- Time to Load Up on Home Builders?
